Scholarlink

Background <p>Evidence concerning the association between excessive total bile acid (TBA) concentrations and adverse perinatal outcomes in the recent Chinese guidelines for intrahepatic cholestasis of pregnancy (C-ICP), which recommend including asymptomatic hypercholanemia of pregnancy (AHP) in ICP management, is insufficient. This study aims to investigate the association between adverse perinatal outcomes and maternal TBA concentrations in patients with C-ICP and compare differences in adverse perinatal outcomes between AHP and ICP subgroups in different TBA concentrations.</p> Methods <p>This retrospective cohort study included pregnant individuals with C-ICP (n = 957) who delivered and had regular antenatal examination records available at a hospital in Guangzhou, China, from January 2015 to December 2024. Participants were grouped according to TBA concentrations (low mild (LM), high mild (HM), severe (S), and extremely severe (ES)) and then sub-grouped into AHP and ICP subgroups within each TBA concentration group.</p> Results <p>Multivariate logistic regression models showed that the risk of adverse perinatal outcomes (including preterm birth, indicated preterm birth, meconium-stained amniotic fluid, and admission to the neonatology department) increased with TBA concentration. Compared to the LM group, the rate of adverse perinatal outcomes increased significantly from the S group onwards, reaching its highest rate in the ES group (preterm birth: P-trend &lt; 0.001; indicated preterm birth: <i>P</i>-trend &lt; 0.001; meconium-stained amniotic fluid: P-trend = 0.037; admission to the neonatology department: P-trend &lt; 0.001; gestational age at delivery: P-trend &lt; 0.001; birth weight of newborn: P-trend &lt; 0.001). However, within the ES group, there was no significant difference in the risk of adverse perinatal outcomes between the AHP subgroup and the ICP subgroups. (preterm birth: odds ratio (OR) 0.41, 95% confidence interval (CI) 0.09–2.00; indicated preterm birth: OR 0.75, 95% CI 0.14–4.06; meconium-stained amniotic fluid: OR 0.56, 95% CI 0.14–2.19; admission to the neonatology department: OR 1.65, 95% CI 0.39–7.04; gestational age at delivery: β 0.65, 95% CI − 0.42–1.72; and birth weight of newborn: β 101.7, 95% CI − 129.05–332.45).</p> Conclusion <p>We recommend&#xa0;TBA screening in prenatal care for all pregnant women, not just for those with pruritus. In addition, the AHP population can be followed with&#xa0;ICP-equivalent clinical management, which&#xa0;is indicated when TBA concentration is ≥ 100&#xa0;μmol/L, as it increases the risk of adverse perinatal outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Total bile acid concentrations and adverse perinatal outcomes in chinese intrahepatic cholestasis of pregnancy including asymptomatic hypercholanemia of pregnancy: a retrospective cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月16日

查看全文
  • Lin Yao,
  • Jin Zhou,
  • Zhangmin Tan,
  • Chuo Li,
  • Tiantian He,
  • Yuzhu Yin,
  • Peizhen Zhang

摘要

Background

Evidence concerning the association between excessive total bile acid (TBA) concentrations and adverse perinatal outcomes in the recent Chinese guidelines for intrahepatic cholestasis of pregnancy (C-ICP), which recommend including asymptomatic hypercholanemia of pregnancy (AHP) in ICP management, is insufficient. This study aims to investigate the association between adverse perinatal outcomes and maternal TBA concentrations in patients with C-ICP and compare differences in adverse perinatal outcomes between AHP and ICP subgroups in different TBA concentrations.

Methods

This retrospective cohort study included pregnant individuals with C-ICP (n = 957) who delivered and had regular antenatal examination records available at a hospital in Guangzhou, China, from January 2015 to December 2024. Participants were grouped according to TBA concentrations (low mild (LM), high mild (HM), severe (S), and extremely severe (ES)) and then sub-grouped into AHP and ICP subgroups within each TBA concentration group.

Results

Multivariate logistic regression models showed that the risk of adverse perinatal outcomes (including preterm birth, indicated preterm birth, meconium-stained amniotic fluid, and admission to the neonatology department) increased with TBA concentration. Compared to the LM group, the rate of adverse perinatal outcomes increased significantly from the S group onwards, reaching its highest rate in the ES group (preterm birth: P-trend < 0.001; indicated preterm birth: P-trend < 0.001; meconium-stained amniotic fluid: P-trend = 0.037; admission to the neonatology department: P-trend < 0.001; gestational age at delivery: P-trend < 0.001; birth weight of newborn: P-trend < 0.001). However, within the ES group, there was no significant difference in the risk of adverse perinatal outcomes between the AHP subgroup and the ICP subgroups. (preterm birth: odds ratio (OR) 0.41, 95% confidence interval (CI) 0.09–2.00; indicated preterm birth: OR 0.75, 95% CI 0.14–4.06; meconium-stained amniotic fluid: OR 0.56, 95% CI 0.14–2.19; admission to the neonatology department: OR 1.65, 95% CI 0.39–7.04; gestational age at delivery: β 0.65, 95% CI − 0.42–1.72; and birth weight of newborn: β 101.7, 95% CI − 129.05–332.45).

Conclusion

We recommend TBA screening in prenatal care for all pregnant women, not just for those with pruritus. In addition, the AHP population can be followed with ICP-equivalent clinical management, which is indicated when TBA concentration is ≥ 100 μmol/L, as it increases the risk of adverse perinatal outcomes.